Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 06/26–06/29 | 06/30 | 10,000 sh3 trades | $170.15avg. | $1,701,526.2 | −15.4% | |
Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 06/05 | 06/09 | 25,000 sh5 trades | $165.32avg. | $4,132,990.2 | −61.2% | |
Leslie V. NorwalkDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 06/04 | 06/08 | 1,250 sh | $168.06 | $210,075 | −30.6% |
Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 06/02 | 06/04 | 36,937 sh5 trades | $156.22avg. | $5,770,377.12 | −62.3% | |
Jude OnyiaChief Scientific Officer | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 06/01 | 06/02 | 11,000 sh | $160.25 | $1,762,750 | −29.9% |
Ingrid DelaetChief Regulatory Officer | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 05/29 | 06/02 | 2,261 sh | $156.71 | $354,321.31 | −12.2% |
Jude OnyiaChief Scientific Officer | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 05/27 | 05/29 | 11,000 sh | $155.53 | $1,710,830 | −29.9% |
David W. BoyerChief Corp. Affairs Officer | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 05/26 | 05/28 | 3,888 sh | $156.64 | $609,016.32 | −33.3% |
Kevin Charles GormanDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 05/19 | 05/21 | 245,088 sh | $154.33 | $37,824,431.04 | −32.4% |
Richard F. PopsDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 05/15 | 05/18 | 15,000 sh | $157.65 | $2,364,750 | −30.3% |
Leslie V. NorwalkDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 05/12 | 05/14 | 3,810 sh | $155.01 | $590,588.1 | −61.1% |
Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 01/16 | 01/20 | 36,400 sh2 trades | $132.70avg. | $4,830,298.12 | −20.6% | |
Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/12/15–25/12/16 | 25/12/17 | 6,190 sh2 trades | $152.78avg. | $945,707.1 | −49.8% | |
Darin LippoldtChief Legal Officer | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/12/08 | 25/12/10 | 4,376 sh | $159.65 | $698,628.4 | −9.2% |
Gary A. LyonsDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/12/03 | 25/12/04 | 15,000 sh | $152.61 | $2,289,150 | −11.1% |
Eric BenevichChief Commercial Officer | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/11/28 | 25/12/02 | 5,970 sh | $151.74 | $905,887.8 | −11.7% |
George J. MorrowDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/11/25 | 25/11/26 | 15,000 sh | $143.37 | $2,150,550 | −68.0% |
William H. RastetterDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/11/05 | 25/11/06 | 18,000 sh | $151.82 | $2,732,760 | −30.8% |
Kyle GanoCEO | Neurocrine BiosciencesNBIX | Open-market sale | 25/11/04 | 25/11/04 | 300 sh | $141.97 | $42,591 | −0.2% |
Kevin Charles GormanDirector | Neurocrine BiosciencesNBIX | Open-market sale10b5-1 plan | 25/08/07 | 25/08/11 | 106,322 sh | $126.41 | $13,440,164.02 | −17.1% |